Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

This week, a new paper described how researchers pieced together the entire molecular structure of the protein shell of the HIV virus using GPU-based simulations. This remarkable achievement not only ...

As the HIV virus glides up outside a human cell to dock and possibly inject its deadly cargo of genetic code, there's a spectacularly brief moment in which a tiny piece of its surface snaps open to ...

Seeing a glycoprotein on the envelope of the HIV virus snap open and shut in mere millionths of a second is giving investigators a new handle on the surface of the virus that could lead to broadly ...

Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the condition. UCSF researchers have adapted innovative tools and ...

Duke Human Vaccine Institute (DHVI) investigators used a technique called time-resolved, temperature-jump (TR, T-Jump) small-angle x-ray scattering (SAXS) to capture the spectacularly brief moment ...

Left: Structure of the Human Immunodeficiency Virus (HIV). Note the envelope protein that protects the virus against immunological detection and the small genome consisting of two short strands of RNA ...